India, Sept. 27 -- Mirum Pharmaceuticals Inc. (MIRM) and Incyte (INCY) announced that the U.S. Food and Drug Administration approved Atebrioz (zilurgisertib) tablets for reducing the volume of new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by abnormal bone formation in muscles and connective tissues.
The approved treatment is administered orally once daily at a recommended dose of 100 mg.
Atebrioz was developed by Incyte and licensed to Mirum Pharmaceuticals for worldwide development and commercialization. The companies said the therapy will be distributed through Mirum Access Plus (MAP), a patient support pr...